This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
A synthetic heptapeptide developed by the Russian Institute of Molecular Genetics as an anxiolytic with nootropic properties. Selank reduces anxiety and enhances cognition through GABA-A modulation and BDNF upregulation — without sedation, tolerance, or dependence.
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) created at the Institute of Molecular Genetics of the Russian Academy of Sciences. It was developed as a synthetic analogue of tuftsin, an endogenous tetrapeptide with immunomodulatory properties, extended with additional amino acids to improve stability and add nootropic activity.
It is approved in Russia as an anxiolytic medication — one of the few peptides with regulatory approval for anxiety treatment, and unique in that approval because it produces anxiolytic effects without benzodiazepine-style sedation, tolerance, or physical dependence.
Selank operates through at least two distinct mechanisms: it modulates GABA-A receptors (enhancing the receptor's affinity for endogenous GABA without direct binding to the benzodiazepine site) and upregulates BDNF (brain-derived neurotrophic factor), which supports neuroplasticity, memory consolidation, and resilience to stress. This combination makes it simultaneously anxiolytic and cognitive-enhancing — a profile not shared by conventional anxiolytics.
GABA-A modulation provides anxiolytic effects comparable to low-dose benzodiazepines, but without sedation, cognitive impairment, or the physical dependency benzodiazepines carry.
Selank increases BDNF expression — the primary neurotrophic factor supporting synaptogenesis, neuroplasticity, and memory consolidation. Effects are pro-cognitive alongside anxiety reduction.
Supports long-term potentiation and memory consolidation through BDNF and dopamine pathway modulation — users report improved information retention and mental clarity.
Modulates serotonin and dopamine systems alongside GABA, producing mood-stabilizing effects that reduce anxiety-driven emotional volatility without flattening affect.
Selank enhances adaptive responses to stress — reducing anxious reactivity while maintaining alertness and cognitive performance under pressure.
Derived from tuftsin, selank retains some immune-modulating properties — research shows effects on cytokine balance and natural killer cell activity.
Selank is administered intranasally or subcutaneously. Intranasal delivery is preferred for fast central nervous system access — the olfactory pathway provides direct transport across the blood-brain barrier. Subcutaneous injection is also effective for systemic distribution.
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Intranasal | 250 – 500 mcg per nostril | 1–2x daily | Fastest onset; preferred for cognitive/mood effects |
| Subcutaneous | 300 – 500 mcg | 1–2x daily | Systemic distribution; equally effective for anxiety |
| Cycle | 14–28 days; break of equal length; may repeat | ||
| Storage | Refrigerate solution; stable for 2–3 weeks | ||
Selank is Russian-approved with a published human trial record. Key benchmarks from the available research:
Approved by the Russian Ministry of Health as a prescription anxiolytic-nootropic. One of the few research peptides with full regulatory approval for human use — establishing a clinical safety record that most research peptides lack entirely.
Head-to-head comparison studies in Russia showed selank produced HAM-A anxiety scale improvements comparable to medazepam (a benzodiazepine) — but without sedation, cognitive impairment, or withdrawal syndrome on discontinuation. This is the defining clinical finding.
Animal studies consistently show selank increases BDNF expression in the hippocampus — the brain region most critical for memory consolidation and cognitive resilience. This neuroplasticity effect underlies the nootropic dimension distinct from pure anxiolytics.
Unlike benzodiazepines, which produce physical dependence and rebound anxiety on discontinuation, selank shows no documented withdrawal syndrome in either clinical trials or long-term user reports. The GABA modulation is indirect — enhancing receptor sensitivity rather than direct agonism — which appears to underlie the cleaner discontinuation profile.
Selank is sold for research purposes only. While approved in Russia as an anxiolytic medication, it is not approved by the FDA. The information on this page is educational. Consult a qualified healthcare professional before considering any peptide protocol. Do not use as a substitute for prescribed treatment for anxiety or mental health conditions.
Third-party tested selank with Finnrick Analytics verification. Full COA on every batch. Ships within 24 hours.
Get Started TodayMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.